1[1]Eschbach JW, Abdulhadi MD, Browne JK. Recombinant human erythropoietin in anemic pafients with end - stage renal disease:results of a phase Ⅲ multipenter elinical trial. Ann Intern Med, 1989,111 ;997
2[2]Schreiber S. Howaldt s, schnoor MRecombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N.Engl J Med, 1996,334:619
3[3]Siciliano M, Tomasello D, Millant A. Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology, 1995,12:1132
4[4]Feghali CA, Wright TM Cytokinps in acute and chronic inflammation. Front Biosci, 1997,2:12
5[5]Bertero MT. Culigarix- cappio F Anemia of chronic disorders in systemic autoimmune disease. Haematologica, 1997,82 ( 3 ): 375
6[6]Spivak VL, Barnes DC, Fuchs E、 et al. Serum immunoreactive erythropietin in HIV - infected patients. JAMA, 1989,261: 3104
7[7]Sipsas NV, Kokori SI, Ioannidis IP、 et al. Circulating autoantibodies to erythropoietin are associated with human immunodeficiency virus type 1-related anemia. J Infect Dis, 1999,180(6) :2044
8[8]Moore RD, Keruly JC, Chaisson RE.Anemia and survival in HIV infection. J. Acquir lmmune Defic syndr Hum Retrovivol , 1998,19: 2S
9[9]Mercadante S, Gebbia V, Marrazzo A, et al. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev, 2000,26(4): 303
10[10]Casadevall N. Cellular mechanism of resistance to erythropoietin. Nephrol - Dial - Transplant, 1995,10 supp16:27
